Retinoid differentiation therapy in promyelocytic leukemia

Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t(15;I7) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all‐trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RARα and a novel gene PML. In vivo differentiation therapy with retinoids in APL patients follows strict guidelines related both to the APL cell and the biodisposal of all‐Iran retinoic acid.—Chomienne, C., Fenaux, P., Degos, L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J. 10,1025‐1030 (1996)

[1]  D. Sentero,et al.  Retinoic acid syndrome in acute promyelocytic leukemia. , 1997, Wisconsin medical journal.

[2]  J. L. Napoli.  Retinoic acid biosynthesis and metabolism , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[4]  RT-PCR in acute promyelocytic leukemia: second workshop of the European Retinoic Group, Paris, France, 17-18 December 1994. , 1996, Leukemia.

[5]  P. Fenaux,et al.  In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. , 1995, Leukemia.

[6]  P. Fenaux,et al.  All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Warrell,et al.  9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. , 1995, Blood.

[8]  J. Wiley,et al.  Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. , 1995, Leukemia.

[9]  E. Macintyre,et al.  Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. , 1995, Blood.

[10]  T. Naoe,et al.  Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). , 1995, Leukemia.

[11]  A. Zelenetz,et al.  Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). , 1995, Blood.

[12]  C. Peschle,et al.  Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. , 1995, Cancer research.

[13]  P. Maslak,et al.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. , 1994, Blood.

[14]  G. Zauli,et al.  All-trans retinoic acid and induction of apoptosis in acute promyelocytic leukemia cells. , 1994, Leukemia & lymphoma.

[15]  R. Warrell,et al.  Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. , 1994, Leukemia.

[16]  C. Chastang,et al.  Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia , 1994, The Lancet.

[17]  N. Stuurman,et al.  The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.

[18]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.

[19]  M. Kris,et al.  Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. , 1993, Journal of the National Cancer Institute.

[20]  Myriam Alcalay,et al.  The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.

[21]  P. Adamson,et al.  Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. , 1993, Cancer research.

[22]  H. Dombret,et al.  Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. , 1993, Leukemia.

[23]  S. Waxman,et al.  Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. , 1993, Blood.

[24]  H. Dombret,et al.  Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. , 1992, Leukemia.

[25]  P. Chambon,et al.  Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. , 1992, The EMBO journal.

[26]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[27]  K. Umesono,et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.

[28]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[29]  E. Besa.  Acute promyelocytic leukemia. , 1991, Blood.

[30]  H. Dombret,et al.  Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid , 1990, The Lancet.

[31]  T G Cotter,et al.  HL‐60 cells induced to differentiate towards neutrophils subsequently die via apoptosis , 1990, Clinical and experimental immunology.

[32]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.